Embolotherapy Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)

Embolotherapy Market Trends and Growth Drivers

Product Launches and Technological Innovations Are Major Market Trends

• The past years have experienced swift growth in the launch of new embolic agents and support devices.
• For example, in March 2024, CERENOVUS Inc. launched the TRUFILL n-BCA liquid embolic system. It is a procedural set usable in two configurations, with the accessories required to prepare and administer the n-BCA liquid embolic system in one single sterilized set.
• Likewise, Terumo Medical Corporation unveiled the AZUR HydroPack coil system in December 2023. It occludes vessels by leveraging advanced hydrogel technology.
• In October 2023, Sirtex Medical launched the LAVA liquid embolic system, engineered specifically for peripheral vascular hemorrhage. This system offers diverse options for volume and thickness, offering tailored treatments based on individual patient needs.
• Moreover, the development of drug-eluting beads, new embolic agents, and radioembolization procedures has enhanced the efficacy and safety of embolotherapy devices.
• For instance, Boston Scientific has developed Embozene TANDEM drug-eluting microspheres for embolization with localized chemotherapy, to deliver drugs directly to the tumor site, thereby improving efficiency.
• Furthermore, Merit Medical Systems’ Embosphere microspheres have a uniform size and shape to ensure predictable blood vessel occlusion in procedures such as uterine fibroid embolization and hypervascular tumor treatment.

Expansion of Patient Pool and Healthcare Infrastructure Drive Market Growth

The embolotherapy market is witnessing growth on account of an increase in the number of patients seeking embolization treatments for hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), varicose veins, and aneurysms. According to the Centers for Disease Control and Prevention (CDC), almost 10,000 people in the U.S. die each year from aortic aneurysms, which shows the unmet need for such procedures.

The market is also bolstered by the rise in the demand for minimally invasive surgical technologies. These procedures require much less time to recover from in contrast to traditional surgeries, while reducing the chances of complications and infections. Since they are precise and image-guided, they also cause less damage to surrounding tissues. Further, the advancements in imaging, embolic agents, and catheter technology make these therapies increasingly effective.

To address the rising cases of chronic diseases, governments across the globe are significantly investing to improve the healthcare infrastructure and advance medical facilities. As per the World Health Organization, global expenditure on health rose to a staggering USD 9.8 trillion in 2021, accounting for 10.35% of the worldwide GDP. This increase supports the establishment of new hospitals and the procurement of high-tech medical equipment.

The U.S., Japan, and Germany are seeking to modernize their healthcare infrastructure by purchasing high-tech equipment and training professionals to employ minimally invasive surgical technologies. Moreover, in emerging economies, such as Brazil, China, and India, well-equipped hospitals and specialized interventional radiology units are being constructed.

Notably, the expansion of services to places that lack access through mobile health units, satellite healthcare centers, and helps address chronic diseases and boosts the demand for medical products.

Increasing Prevalence of Chronic Diseases also Helps Market Advance

Prolonged exposure to four modifiable lifestyle behaviors, namely smoking, unhealthy diet, alcohol consumption, and physical inactivity, often results in chronic diseases, including stroke, diabetes, obesity, metabolic syndrome, chronic obstructive pulmonary disease, and various types of cancer. Chronic diseases are a major healthcare burden affecting high-income as well as low- and middle-income countries (LMICs). Cancer, hepatitis, and central nervous system disorders are some of the chronic diseases that require advanced treatment.

The rise in the acceptance of image-guided procedures provides a great opportunity to the global embolotherapy market. They employ , fluoroscopy, and CT, which allow surgeons to achieve high accuracy in embolization with minimal tissue damage during navigation. Essentially, the market is growing due to the rising consciousness of the benefits of minimally invasive, image-guided treatments.

Furthermore, the transition toward value-based care, where value is placed over cost and on improved outcomes at a reduced cost, propels the demand for embolic agents and support devices.

Embolotherapy Market Analysis

Product Analysis

Embolic agents dominate the embolotherapy market in 2024 with revenue of USD 3,535.3 million. The increasing use of embolic agents in various interventional radiological procedures is the primary reason for this category's dominance on the market.

Furthermore, due to the advancements in such agents, such drug-eluting microspheres, as calibrated microspheres for bland embolization, and radioactive yttrium-90 microspheres, for primary or secondary diseases of the liver, the category is expected to advance at the highest rate over the forecast period.

The escalating rates of HCC directly drive the demand for microspheres, as they are widely used for the treatment of HCC. As per the American Cancer Society, more than 850,000 diagnoses of liver cancer are registered around the world every year.

The ongoing research on developing biodegradable and multifunctional microspheres is another key driver for this category. These microspheres can offer an effective treatment for HCC by conjugating therapeutic radionuclides with chemotherapeutic agents.

The products evaluated in this report are:

• Embolic Agents (Larger and Faster-Growing Category)
  • Microspheres
  • Embolic coils
  • Liquid embolic agents
  • Embolic plug systems
  • Detachable balloons
• Support Devices
  • Microcatheters
  • Guidewires

Procedure Analysis

Transcatheter arterial embolization (TAE) leads the embolotherapy market, and it is expected to be the fastest-growing category, at a CAGR of 8.9%, during the forecast period. This is attributed to the proliferating demand for minimally invasive procedures and the rapidly growing geriatric population. TAE is effective and well-tolerated in patients with ruptured HCCs, and it is preferred over transarterial chemoembolization (TACE) and transarterial radioembolization (TARE)/selective internal radiation therapy (SIRT).

The procedures analyzed here are:

• Transcatheter Arterial Embolization (TAE) (Largest and Fastest-Growing Category)
• Transarterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT)
• Transarterial Chemoembolization (TACE)

Indication Analysis

Cancer is the largest category in the embolotherapy market, and it is projected to reach a value of USD 2,736.4 million in 2030. Embolization is majorly used for the treatment of cancer, including kidney and liver cancers. It has the advantage directly detecting and targeting tumors, while minimizing the impact on the tissues around the embolization site. Superior imaging and more-potent embolic agents make embolization a far more potent oncological procedure.

The indications evaluated here are:

• Cancer (Largest and Fastest-Growing Category)
  • Kidney
  • Liver
  • Others
• Peripheral Vascular Diseases
• Neurological Diseases
  • Cerebral aneurysms
  • Arteriovenous malformations & fistulas
• Urological & Nephrological Disorders
• Gastrointestinal Disorders

End User Analysis

The hospitals and clinics category will generate the highest revenue, of USD 3,182.1 million, in 2024. The major end users of embolotherapy devices and embolic agents are large hospitals, small clinics, and critical care units. The increasing adoption of minimally invasive surgical procedures, including vascular, neurological, and urological interventions, is driving the volume of embolotherapy procedures at these places.

Well-equipped hospitals with infrastructure that supports comprehensive patient care, such as departments of interventional radiology, are preferred for embolization procedures. Hospitals also have more patients in comparison to ambulatory surgical centers and thus, create a higher demand for embolotherapy devices and embolic agents.

Additionally, the increasing buying power of major healthcare providers and availability of reimbursement for embolotherapy procedures in the U.S. and other major European markets drive the growth of this category.

The end users evaluated here are:

• Hospitals & Clinics (Largest and Fastest-Growing Category)
• Ambulatory Surgical Centers (ASCs)
• Others

Geographical Analysis

North America is expected to generate the highest market revenue, of USD 2,449.7 million, in 2030. The increasing prevalence of indications that require embolization procedures, established healthcare ecosystem, and development of advanced embolic agents by the players operating in the region propel the North American market. The American Cancer Society estimated 1.9 million cancer cases and 609,360 related deaths in the U.S. in 2022.

Further, the rising geriatric population is a key driver for the market in the region as these people are highly vulnerable to cancer and other severe diseases. According to the Population Reference Bureau, the number of people in the age group of 65 and above in the U.S. is predicted to increase by a massive 47%, to 82 million by 2050 from 58 million in 2022.

APAC is expected to emerge as the fastest-growing region for embolotherapy, at a CAGR of 9.7%, during the forecast period. China and India are experiencing rapid economic growth, leading to the increasing consumer spending and investment in healthcare. The region also has a rapidly growing population, which creates a substantial market for embolotherapy.

The increasing foreign direct investment (FDI) into the regional healthcare industry also encourages businesses in the market to innovate. As per the IBEF, the country’s medical and surgical appliance sector received FDI worth USD 3.28 billion from April 2000 to March 2024. Moreover, FDI in hospitals and diagnostic centers stood at USD 10.26 billion for the same period.

Another key driver for the market in the region is its growing medical tourism industry. Compared to the U.S. and Western European countries, India, Singapore, Malaysia, Vietnam, Thailand, and other APAC nations offer less-costly treatments for even complex conditions, including cancers.

The regions and countries we have analyzed here are:

• North America (Largest Regional Market)
  • U.S. (Larger and Faster-Growing Country Market)
  • Canada
• Europe
  • Germany (Largest and Fastest-Growing Country Market)
  • Spain
  • France
  • U.K.
  • Italy
  • Rest of Europe
• Asia-Pacific (APAC) (Fastest-Growing Regional Market)
  • China (Largest and Fastest-Growing Country Market)
  • India
  • Japan
  • South Korea
  • Singapore
  • Rest of APAC
• Latin America (LATAM)
  • Brazil (Largest and Fastest-Growing Country Market)
  • Mexico
  • Rest of LATAM
• Middle East & Africa (MEA)
  • Saudi Arabia (Largest and Fastest-Growing Country Market)
  • South Africa
  • Rest of MEA

Embolotherapy Market Share

The embolotherapy market is fragmented in nature because there are numerous multinationals and smaller, specialized enterprises. They all specialize in different products for vascular embolization, tumor embolization, and uterine fibroid embolization. Embolotherapy is applied in numerous fields, such as oncology, interventional radiology, and vascular surgery, which leads to a diversity of products and services, thus widening the scope for new players. Further, different countries have different market dynamics, regulations, and customer preferences, which further contributes to a fragmented landscape.

Embolotherapy Market Company News

• In June 2024, Boston Scientific Corporation declared its intentions to acquire Silicon Valley medical device company Silk Road Medical Inc. The latter offers products to prevent strokes in patients with carotid artery disease through a minimally invasive procedure known as transcarotid artery revascularization.
• In May 2024, Merit Medical Systems Inc. announced the FDA 510(k) clearance for its Siege Vascular Plug, along with the launch of the Bearing nsPVA Express prefilled syringe in the U.S. and Australia.
• In September 2023, Sirtex Medical announced a worldwide exclusive distribution agreement with Magle Group, a Sweden-based CDMO and seller of degradable starch microshperes. Under the partnership, Sirtex Medical exclusively distributes Magle Group's EmboCept S DSM 50 μm chemoembolization product in existing and new markets.